Greener Megan R, Storr Sarah J
Biodiscovery Institute Phase 3, Entrance 2, Building 43, University of Nottingham, University Park, Nottingham NG7 2RD, UK.
NeuroSci. 2022 Aug 25;3(3):494-509. doi: 10.3390/neurosci3030035. eCollection 2022 Sep.
We are amidst a global addiction crisis, yet stigmas surrounding addiction counterintuitively prevail. Understanding and appreciating the neurobiology of addiction is essential to dissolve this stigma and for the development of new pharmacological agents to improve upon currently narrow therapeutic options. This review highlights this and evaluates dopamine-and-cAMP-regulated phosphoprotein, Mr 32 kDa (DARPP-32) as a potential target to treat various forms of substance abuse. Despite the proven involvement of DARPP-32 in addiction pathophysiology, no robust investigations into compounds that could pharmacologically modulate it have been carried out. Agents capable of altering DARPP-32 signalling in this way could prevent or reverse drug abuse and improve upon currently substandard treatment options.
我们正处于一场全球成瘾危机之中，然而，围绕成瘾的污名却反常地普遍存在。理解和认识成瘾的神经生物学对于消除这种污名以及开发新的药物制剂以改善目前有限的治疗选择至关重要。这篇综述强调了这一点，并评估了多巴胺和环磷酸腺苷调节的磷蛋白，32 kDa（DARPP - 32）作为治疗各种形式药物滥用的潜在靶点。尽管已证实DARPP - 32参与成瘾病理生理学，但尚未对能够从药理学上调节它的化合物进行深入研究。能够以这种方式改变DARPP - 32信号传导的药物可以预防或逆转药物滥用，并改善目前不合格的治疗选择。
